SU427711A1 - MEANS FOR DILUTION OF MICROTAGE AND PURULENT-NECROTIC MASSES, 15 cJ - Google Patents
MEANS FOR DILUTION OF MICROTAGE AND PURULENT-NECROTIC MASSES, 15 cJInfo
- Publication number
- SU427711A1 SU427711A1 SU1696372A SU1696372A SU427711A1 SU 427711 A1 SU427711 A1 SU 427711A1 SU 1696372 A SU1696372 A SU 1696372A SU 1696372 A SU1696372 A SU 1696372A SU 427711 A1 SU427711 A1 SU 427711A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- purulent
- microtage
- dilution
- necrotic masses
- necrotic
- Prior art date
Links
- 238000010790 dilution Methods 0.000 title 1
- 239000012895 dilution Substances 0.000 title 1
- 239000000443 aerosol Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
1one
Изобретение отиоаитс к производству лекарственных 1препа.ратов.The invention otoaits for the production of medicinal 1prep.ratov.
Из,вестен Опособ разжижени мокроты прл некоторых заболеваеи х легких с использованием (протеолипичесюнх ферментов химотрипчзина и трипсина путем, iHanp«Metp, и.нгал ции этих npenaip.aTOiB.Of course, Sputum Liquefaction Technique is known in some lung diseases using (chymotripchzin and trypsin proteolipic enzymes by, iHanp "Metp, and inhalation of these npenaip.aTOiB.
Предложено применение ферментного препарата пигролитина IB «ачестве средства дл разж1ИЖеии1Я мокроты и гнойно-некротиче-смих масс.The use of the enzyme preparation pygrolitin IB was proposed as an agent for diluting sputum and purulent-necrotic masses.
Г|И1Гролит1И1Н -вл етгс ферментным препаратом , обладающим протеолиническдам действием . Лигролитм« - аморфный порошок белого или белого с желтоватым оттенком цвета. Растворим в 1воде и IB И3|0то(ническом 0,9%-«ом растворе хлорида иатри . При нагревании выше 30°С И изме:нвн1ии рН пиже 5,0 или выше 8,0 инактивируетс .Г | И1Гролит1И1Н -вл егс with enzyme preparation, possessing proteolinic action. Ligrolitm "- amorphous powder of white or white with a yellowish tinge color. It is soluble in water and IBI3 | 0to (a non-toxic 0.9% - iodine solution of sodium chloride. When heated above 30 ° C and measured: no matter the pH of the pH is 5.0 or above 8.0, it is inactivated.
По овоему физиолопическому действию глгрол1итин соответствует действию животных протеаз (химотрипсину, трипсину), введенных в организм извне. Он опособен расщепл ть в зиие эксудаты, омертвевшие уч астки тканей , фибри«оз1ные образовани .According to its physiological action, glgrol1itin corresponds to the action of animal proteases (chymotrypsin, trypsin) introduced into the body from the outside. It is specific to split exudates in the marginal zone, necrotic tissue tissues, and fibrous formations.
При .аэрозольном применении гигролитина в дыхательных пут х создаютс концентрации препарата, разжзижающие густую в зкую мокроту 1И способствующие свободной эвакуации СЛИ81И :и гноЙ1НО--.некрот1ичеоюих масс. ВIn case of aerosol application of hygrolitine in the respiratory tract, drug concentrations are created, which dilute the thick viscous sputum 1 and promote free evacuation of the SLI: and the gnoi-necrotic necrosis. AT
результате (восстанавливаетс фу1нкц|И мерцательного эпители и сллз1истых желез дыхательных путей, улучшаетс вентил ци легмих и улучшаетс дренаж придаточных пазух 5 иоса.as a result, the ciliated epithelium and the slitous glands of the respiratory tract are restored, the ventilation of the lungs is improved, and the drainage of the paranasal sinuses of the iosus is improved.
Гигролитин примен ют в аиде аэрозол дл ингал ций. Аэрозоль пигролитина дл ингал ции получают либо примен воду, либо изотон ичеокий раствор хлорида матри . Кон0 центрац1И; гигролитина в 1 мл раствора должна быть 25 ПЕ. Обьгано на одну ингал цию готов т 3 мл раСтвора. Ингал ции провод т 1-2 раза в сутки в течение 15-20 мин. Длительность курса лечени 3-5 дней. Дл 5 ингал ции используют распылители типа АИ-1, АИ-2, УН и др.Hygrolitin is used in inhalation aerosol aerosol. Pygrolitin aerosol for inhalation is obtained either by using water or an isotonic chemical matrix solution. Concentration; Hygrolitin in 1 ml of solution should be 25 PE. Charged for one inhalation, prepared with 3 ml of solution. Inhalations are carried out 1-2 times a day for 15–20 minutes. The duration of treatment is 3-5 days. For 5 inhalations, sprays of type AI-1, AI-2, UN, etc. are used.
Во врем лечени аэрозолем ригролитина может возНиКать ощущение горечи во рту, чувство першени в гортави. (После ингал 0 ЦИ1И полость рта следует прополоскать водой). Гигролитин выпускают в герметически закрытых флаконах по 250 ПЕ.During treatment with a spray aerosol, rigrolitin may have a feeling of bitterness in the mouth, a feeling of tarsia in the gortavi. (After inhal 0 CI1I, the oral cavity should be rinsed with water). Gigrolitin released in hermetically sealed vials of 250 PE.
Препарат хран т в сухом, защищенном от света месте при температуре не выше 4°С.The drug is stored in a dry, dark place at a temperature not exceeding 4 ° C.
П р le д-м € т 1И 3 о б р е т е н и PR le dm € t 1I 3 about b ete n i
Применечше ферментного препарата гигролитина в Качестве средства дл разжижени 30 мокроты и гнойно-некротических чмасс.It uses the enzyme preparation hygrolitine as a means for diluting 30 sputum and purulent-necrotic masses.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU1696372A SU427711A1 (en) | 1971-08-24 | 1971-08-24 | MEANS FOR DILUTION OF MICROTAGE AND PURULENT-NECROTIC MASSES, 15 cJ |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU1696372A SU427711A1 (en) | 1971-08-24 | 1971-08-24 | MEANS FOR DILUTION OF MICROTAGE AND PURULENT-NECROTIC MASSES, 15 cJ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU427711A1 true SU427711A1 (en) | 1974-05-15 |
Family
ID=20487647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU1696372A SU427711A1 (en) | 1971-08-24 | 1971-08-24 | MEANS FOR DILUTION OF MICROTAGE AND PURULENT-NECROTIC MASSES, 15 cJ |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU427711A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2360685C1 (en) * | 2007-12-25 | 2009-07-10 | Институт прикладной механики УрО РАН | Softening agent for thick and viscous pus |
-
1971
- 1971-08-24 SU SU1696372A patent/SU427711A1/en active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2360685C1 (en) * | 2007-12-25 | 2009-07-10 | Институт прикладной механики УрО РАН | Softening agent for thick and viscous pus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6328411B2 (en) | ||
| CN107899006A (en) | Pharmaceutical composition of nasal irrigation and preparation method thereof | |
| SU427711A1 (en) | MEANS FOR DILUTION OF MICROTAGE AND PURULENT-NECROTIC MASSES, 15 cJ | |
| Beermann et al. | Lipoid pneumonia: an occupational hazard of fire eaters | |
| Harrington et al. | A case of Sjögren's disease with scleroderma | |
| CA2383357A1 (en) | Use of tosylchloramide(s) for treating diseases of the skin, mucous membranes, organs and tissues | |
| Gross et al. | Ludwig angina in childhood | |
| Fabricant et al. | Hydrogen Ion Concentration of Nasal Secretion in Situ in Infants and in Children: With a Comment on pH values in Pediatric Nasal Medication | |
| US5900401A (en) | Remedy for respiratory-tract viral disease | |
| Fenton | Local Use of Sulfathiazole in Otolaryngologic Practice | |
| Sandberg et al. | Lepromatous leprosy of the larynx | |
| RU2665959C1 (en) | Spray for emergency prevention of acute respiratory viral infections | |
| Slotkowski | Formation of mucous membrane lesions secondary to prolonged use of one per cent aqueous gentian violet | |
| RU2144375C1 (en) | Method of treatment of children with stenosing laryngotracheitis | |
| CN1965912B (en) | Application of Chinese medicine polygala root as in-vitro spermaticide and method for preparing the medicament thereof | |
| CN102686232B (en) | Polysaccharide polymers from tamarind seeds for the treatment of dry cough | |
| Locket | Barbiturate deaths | |
| CN101897726A (en) | Traditional Chinese medicinal powder for treating oral ulcer | |
| Gaiger | Glanders in man: A second attack after apparent recovery | |
| KR880701100A (en) | Cold Therapy Kit, Cold Therapy Medicine and Uses thereof | |
| Anderson et al. | The infectivity of the secretions and the desquamating scales of measles | |
| Morrow | Drug Eruptions; a Clinical Study on the Irritant Effects of Drugs Upon the Skin | |
| RU2119342C1 (en) | Herbs species n 2 with common restorative effect | |
| Semon | Eight cases of Lupus vulgaris treated with pyotropin | |
| SU1621939A1 (en) | Method of treating pneumomycosis |